Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

Shinichi Komiyama,Kazuyoshi Kato,Yuki Inokuchi,Hirokuni Takano,Takashi Matsumoto,Atsushi Hongo,Mikiko Asai-Sato,Atsushi Arakawa,Shoji Kamiura,Tsutomu Tabata,Nobuhiro Takeshima,Toru Sugiyama

Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

2019

Shinichi Komiyama
Kazuyoshi Kato
Yuki Inokuchi
Hirokuni Takano
Takashi Matsumoto
Atsushi Hongo
Mikiko Asai-Sato
Atsushi Arakawa
Shoji Kamiura
Tsutomu Tabata
Nobuhiro Takeshima
Toru Sugiyama

Background This was the first large-scale prospective observational Japanese study evaluating the safety and efficacy of bevacizumab combined with paclitaxel and carboplatin for newly diagnosed advanced ovarian cancer.

Keywords:

Taxane
General surgery
Ovarian cancer
Bevacizumab
Carboplatin
Paclitaxel
Chemotherapy
Medicine
Observational study
Gastroenterology
Clear cell carcinoma
Bowel resection
Adverse effect
Internal medicine
Gastrointestinal perforation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations